

10 June 2025

ASX Announcement

Nasodine Phase 3 Common Cold Trial Published

- **Phase 3 common cold trial from 2019 now published in peer-reviewed, high-impact journal**
- **Conclusion: “Nasodine is an effective and clinically meaningful treatment for the common cold”**
- **Nasodine was “safe and well tolerated”**
- **Where treatment was started in the first 24h after symptom onset, Nasodine reduced overall cold severity by 40% compared with saline nasal spray**

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) is pleased to announce that the results of its first Phase 3 clinical trial of Nasodine Nasal Spray (**Nasodine**) as a treatment for the common cold (conducted in 2019) have now been published in *Frontiers in Medicine*, a prestigious, high-impact journal. The paper is titled: “Povidone-iodine nasal spray (Nasodine®) for the common cold: a randomized, controlled, double-blind, Phase III clinical trial,” and is publicly available to review here: <https://doi.org/10.3389/fmed.2025.1565069>

This is the first published clinical study that supports the efficacy of Nasodine as a treatment for the common cold. The conclusion of the paper includes:

“In the current study, Nasodine 0.5% PVP-I nasal spray demonstrated a consistently positive benefit in reducing overall cold severity outcomes compared with saline nasal spray. The benefit of Nasodine was most evident in its impact on functional impairment (quality of life) scores, where the results were statistically significant and clinically meaningful. In subjects who started treatment within the first 24 h after symptom onset, the benefit of Nasodine over saline nasal spray was approximately 40%. It was safe and well tolerated. Nasodine is an effective and clinically meaningful treatment for the common cold.”

The trial was conducted in 2019, with headline results disclosed in the Company’s Prospectus (p. 20). In 2020, the Company applied for approval of Nasodine with the TGA (Therapeutic Goods Administration) and because the 2019 trial results were central to that application, publication of the trial details was delayed until conclusion of the TGA review and subsequent appeals by Firebrick, including an appeal to the AAT (Administrative Appeals Tribunal).

“The AAT appeal led to a detailed review and re-analysis of the trial data by clinical and statistical experts,” said Firebrick executive Chairman, Dr Peter Molloy. “The published paper incorporates those perspectives and analyses, leading to a much richer and more accurate understanding of the trial results.”

Dr Tom Polasek who led the study as Principal Investigator is a clinical pharmacologist and Adjunct Senior Research Fellow at the Monash University Center for Medicine Use and Safety.

“Clinically and scientifically, this was an important trial, being the first pivotal study to demonstrate that a topical agent like povidone-iodine, which targets the viral cause of colds, can be an effective treatment for upper respiratory infections,” said Dr Polasek. “Based on the results of this trial, it is clear that Nasodine offers real benefits as a treatment for the common cold, especially if used early in the illness.”

Dr Molloy added: “This paper will become an important addition to the marketing of Nasodine to healthcare professionals in all markets where the product is currently sold.”

Webinar to be held today

Dr Molloy will be conducting a webinar at 9am (AWST)/11am (AEST) today which is intended to provide an opportunity to shareholders and potential investors to learn more about the impact of the clinical trial publication and to receive updates on the Company's future plans and activities, with a short Q&A segment following the primary presentation.

Investors are encouraged to attend and to register for the webinar using the following link:

https://us02web.zoom.us/webinar/register/WN_OHObokvnS3e0vbEyFtIJeg

An online link to a recording of the webinar will be available through the Company's website.

This announcement has been authorised for release by the Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick recently introduced Nasodine in the United States, Singapore and Fiji and South Pacific, with an agreement in place to also manufacture and launch Nasodine in the Philippines.

Media enquiries:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com